Does gadoxetate disodium affect MRE measurements in the delayed hepatobiliary phase?

M. Plaikner¹ · C. Kremser¹ · H. Zoller² · M. Steurer¹ · B. Glodny¹ · W. Jaschke¹ · B. Henninger¹

Abstract

Objectives To assess if the administration of gadoxetate disodium (Gd-EOB-DTPA) significantly affects hepatic magnetic resonance elastography (MRE) measurements in the delayed hepatobiliary phase (DHBP).

Methods A total of 47 patients (15 females, 32 males; age range 23–78 years, mean 54.28 years) were assigned to standard hepatic magnetic resonance imaging (MRI) with application of Gd-EOB-DTPA and hepatic MRE. MRE was performed before injection of Gd-EOB-DTPA and after 40–50 min in the DHBP. Liver stiffness values were obtained before and after contrast media application and differences between pre- and post-Gd-EOB-DTPA values were evaluated using a Bland-Altman plot and the Mann-Whitney-Wilcoxon test. In addition, the data were compared with regard to the resulting fibrosis classification.

Results Mean hepatic stiffness for pre-Gd-EOB-DTPA measurements was 4.01 kPa and post-Gd-EOB-DTPA measurements yielded 3.95 kPa. We found a highly significant individual correlation between pre- and post-Gd-EOB-DTPA stiffness values (Pearson correlation coefficient of $r = 0.95$ ($p < 0.001$) with no significant difference between the two measurements ($p = 0.49$)). Bland-Altman plot did not show a systematic effect for the difference between pre- and post-stiffness measurements (mean difference: 0.06 kPa, SD 0.81). Regarding the classification of fibrosis stages, the overall agreement was 87.23% and the intraclass correlation coefficient was 96.4%, indicating excellent agreement.

Conclusions Administration of Gd-EOB-DTPA does not significantly influence MRE stiffness measurements of the liver in the DHBP. Therefore, MRE can be performed in the DHBP.

Key Points

- MRE of the liver can reliably be performed in the delayed hepatobiliary phase.
- Gd-EOB-DTPA does not significantly influence MRE stiffness measurements of the liver.
- MRE performed in the delayed hepatobiliary-phase is reasonable in patients with reduced liver function.

Keywords Magnetic resonance imaging · Elastography · Liver · Contrast media · Fibrosis

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| DHBP        | Delayed hepatobiliary phase |
| F0-4         | Fibrosis stage 0-4 |
| Gd-EOB-DTPA  | Gadoxetate disodium |
| kPa          | Kilopascal |
| min          | Minutes |
| ml/s         | Millilitre/second |
| MRE          | Magnetic resonance elastography |
| MRI          | Magnetic resonance imaging |
| ROI          | Region of interest |
| SD           | Standard deviation |
| T            | Tesla |

Introduction

Magnetic resonance elastography (MRE) is increasingly used to obtain information regarding tissue stiffness, particularly of the liver, and is comparable to the performance of ‘virtual palpation’ [1]. MRE has been described as an accurate tool for use in hepatic magnetic resonance imaging (MRI) to detect...
and classify fibrosis in the early stages before morphological changes have occurred [2, 3]. In daily clinical routine, MRE can be performed complementary to diagnostic hepatic MRI. Due to its accurate and non-invasive characteristics for analysing the hepatic parenchyma and lesions, gastroenterologists increasingly request hepatic MRE in addition to standard, contrast-enhanced liver imaging. At our department, MRE has already been integrated into the routine hepatic MRI protocol, depending on the assigned problem.

The liver-specific contrast medium gadoxetate disodium (Gd-EOB-DTPA), also known as Primovist in Europe or Eovist in North America (Bayer Schering Pharma AG), is widely used and has outstanding benefits for liver evaluation [4]. It allows standard dynamic and additional delayed hepatobiliary phase (DHBP) imaging. Gd-EOB-DTPA is taken up by normal hepatocytes, selectively increasing T1 relaxation of normal hepatic tissue in the DHBP and therefore enabling the detection of small tumorous lesions. Thus, liver-specific contrast media have a central role in hepatic MRI with wide acceptance of the prolonged examination time [5]. As Gd-EOB-DTPA uptake may be delayed due to a reduced liver function [6], at our department DHBP imaging in patients with clinically suspected reduction in liver function is always performed 40–50 min after the intravenous injection of Gd-EOB-DTPA, as a second, separate examination. During the waiting interval, a short examination with another patient is carried out (e.g. MRI of the knee or the lumbar spine). Many other institutions perform the DHBP 20 min after contrast administration and use the waiting time to perform other sequences that are not significantly influenced by contrast administration, e.g. heavily T2-weighted turbo spin-echo sequences or diffusion-weighted imaging (DWI) [7].

The purpose of our study was to assess if Gd-EOB-DTPA administration affects hepatic MRE measurements in DHBP. Therefore, we compared hepatic MRE results for each patient before and after Gd-EOB-DTPA administration.

### Material and methods

#### Patients

We retrospectively enrolled 47 patients referred to our department (Department of Radiology, Medical University of Innsbruck) between August 2016 and January 2017 from the gastroenterological department to perform a standardised hepatic MRI, including Gd-EOB-DTPA administration with DHBP imaging and hepatic MRE. Inclusion criteria were a minimum age of 18 years as well as an entirely performed hepatic MRI protocol (Table 1), especially including hepatic MRE performed both before contrast media injection and after 40–50 min in DHBP. Because of the retrospective nature of this study, institutional review board approval was granted by means of a general waiver (Local Research Ethics Committee, Medical University of Innsbruck; 20 February 2009).

#### MRI

MRI was performed in the supine position using a 1.5T MRI scanner (Magnetom AvantoFit, Siemens Healthineers) with an 18-channel body phased-array surface coil. The succession of sequences used for our hepatic MRI protocol is shown in Tables 1 and 2, along with the respective imaging parameters.

Patients received 10 ml of Gd-EOB-DTPA via manual injection through a peripheral intravenous line inserted at the cubital fossa or forearm, with an approximate injection rate of 1.5–2.0 ml/s, followed by a 20-ml saline flush. Hepatic MRE was performed before and 40–50 min after Gd-EOB-DTPA administration (i.e. in DHBP). Mechanical 60-Hz vibrations were applied using a circular passive acoustic driver (Resoundant, Inc.) placed against the right abdominal wall and fixed using an elastic band. A two-dimensional commercial phase-contrast gradient-echo (GRE) sequence as provided

| Table 1 Succession of sequences used for the hepatic MRI protocol |
|------------------|------------------------------------------|
| Temporal numbering | Designation of the sequence               |
| 1                 | Transverse T2w Half-Fourier-Acquired     |
|                   | Single-shot Turbo Spin-Echo (HASTE)      |
| 2                 | Transverse spin-echo-based diffusion-     |
|                   | weighted echo planar imaging (SE-DWI)    |
| 3                 | Transverse T1 3D Multiecho Dixon VIBE    |
|                   | (T1 VIBE q-dixon)                         |
| 4                 | MRE (3 slices)                            |
| 5                 | Transverse volume-interpolated breath-    |
|                   | hold examination (VIBE)-DIXON (native)    |
| 6                 | Gd-EOB-DTPA injection + Dynamic VIBE     |
|                   | Controlled Aliasing In Parallel Imaging   |
|                   | Results In Higher Acceleration Factor     |
|                   | (CAIPIRINA)-DIXON-TWIST (late arterial)   |
|                   | with 3 datasets                           |
| 7                 | Transverse VIBE-DIXON                     |
|                   | (venous, ~45 s after injection)           |
| 8                 | Transverse VIBE-DIXON                     |
|                   | (delayed, ~2 min after injection)         |
| 9                 | Transverse fat saturated T2w TSE          |
| 10                | Transverse VIBE-DIXON                     |
|                   | (late, ~7 min after injection)            |
| 11                | 40- to 50-min waiting period (from the    |
|                   | injection) outside the scanner, patient   |
|                   | is repositioned after this period         |
| 12                | Transverse VIBE-DIXON (in the DHBP)       |
| 13                | Coronal VIBE-DIXON (in the DHBP)          |
| 14                | MRE (3 slices)                            |
| Type          | T2w HASTE | SE-DWI | T1 VIBE | VIBE-DIXON | MRE sequence | Dynamic VIBE | T2w TSE |
|--------------|-----------|--------|---------|------------|--------------|--------------|--------|
| Orientation  | Transverse | Transverse | Transverse | Transverse / coronal | Transverse | Transverse | Transverse |
| FOV (mm)     | 380       | 380    | 360     | 380        | 420          | 380          | 380    |
| Slice thickness (mm) | 6       | 6      | 3.5     | 3          | 5            | 3            | 5      |
| Slice gap (mm) | 1       | 1.2    | 0       | 0          | -            | 0            | 1      |
| Slices       | 35        | 31     | 64      | 72         | 1            | 72           | 35     |
| Acquisition matrix | 320 x 256 | 134 x 120 | 160 x 111 | 320 x 195 | 128 x 103 | 288 x 174 | 384 x 216 |
| Parallel imaging factor | 2       | 2      | 3       | 4          | 2            | 4            | 2      |
| TR (ms)      | 1200      | 3500   | 15.6    | 6.68       | 50           | 6.32         | 7725   |
| TE (ms)      | 93        | 59     | 2.38/4.76/7.14/9.52/11.9/14.28 | 2.39 / 4.77 | 23.75 | 2.39 / 4.77 | 96     |
| Flip angle (°) | 90       | 90     | 4       | 10         | 25           | 10           | 90     |
| Echo train length | 102      | 120    | 6       | 2          | 1            | 2            | 18     |
| Fat saturation | no       | Frequency selective | DIXON | DIXON | no | DIXON | Frequency selective |
| b-values     | -         | 50 / 400 / 1000 | -       | -          | -            | -            | -      |
| Averages     | 1         | 1 / 2 / 2 | 1       | 1          | 1            | 1            | 2      |
| Acquisition time (min) | 1:45     | 3:32   | 0:19    | 0:14       | 0:05         | 0:07         | 3:57   |
by the manufacturer was applied, which performs inline calculation of wave and stiffness images together with a 95% confidence map showing areas with less reliable stiffness crossed out [8]. For every patient, three transverse slices through the liver were acquired, with one slice located in the cranial, one in the middle (portal vein at the level of the hilus) and one in the caudal hepatic section.

To assess the hepatic iron state a commercially available 3D multi-echo gradient (GRE) sequence (t1 vibe q-dixon) was used [9].

Data analysis

For each patient, all three transverse hepatic MRE slices before and after Gd-EOB-DTPA administration were evaluated. Stiffness values were reported in kPa units. An as large as possible polygonal region of interest (ROI) was selected in the liver parenchyma of every transverse slice across the 95% confidence region of the acquired stiffness maps. Manual ROI placement was carefully performed by one radiologist with over 6 years’ experience in liver imaging (PM) examining wave images for proper wave propagation and using the magnitude image to avoid major vessels, liver surface and artefacts (especially movement). For further analysis, the mean values of the three polygonal ROIs were used. Patients were classified by the authors into four fibrosis stages according to their mean stiffness value, based on values from the actual literature [10, 11]: F0 = 0–2.5 kPa, F1 = 2.5–3 kPa, F2 = 3–4.4 kPa, F3 = 4.4–7 kPa, and F4 > 7 kPa. Hepatic R2* values were obtained from R2* maps provided by the t1 vibe q-dixon sequence at identical slice positions and checked for iron overload [12] based on the classification recommended by the EASL International Consensus Conference on Haemochromatosis [13].

Statistical analysis

Statistical calculations were performed using the R Project for Statistical Computing [14]. The Shapiro–Wilk normality test was used to assess the normal distribution of the given population. Because data were not normally distributed, the Mann–Whitney–Wilcoxon test was performed to test for a significant difference between pre- and post-Gd-EOB-DTPA MRE data. Results were considered significant at p-values of <0.05. To determine the correlation between pre- and post-Gd-EOB-DTPA MRE data, Pearson’s correlation coefficient was calculated, and the data were compared using a Bland–Altman plot. To determine the agreement between fibrosis staging data before and after Gd-EOB-DTPA administration, contingency tables were created; Pearson’s chi-squared test was performed, and overall agreement, as well as the Cohen’s Kappa coefficient with equal weights and the two-way intraclass correlation coefficient was calculated using the irr-package for R [15].

Results

A total of 47 patients (15 females and 32 males; age range, 23–78 years; mean age, 54.28 years) were enrolled in this study. All patients had the clinical suspicion of impaired liver function: 14/47 patients were transferred post-liver transplantation, 14/47 had unclear, suspicious liver lesions and 19/47 patients suffered from diffuse liver injury including cirrhosis, fibrosis, iron overload or primary sclerosing cholangitis. Of all patients only one was found to have minimal iron overload (R2* of 102 1/s).

The mean area of all polygonal ROIs was 48.18 cm² (range, 12.05–155.23 cm²). The mean hepatic stiffness values of all pre- and post-Gd-EOB-DTPA ROI measurements were 4.01 kPa (1.73–12.81, median 3.20) and 3.95 kPa (2.03–9.65, median 3.10), respectively (Fig. 1).

The individual correlation between pre- and post-Gd-EOB-DTPA stiffness values is shown in Fig. 2 (Pearson correlation coefficient of $r = 0.95$; $p < 0.001$). The Bland–Altman plot (Fig. 3) did not show a systematic effect in the difference between pre- and post-stiffness measurements (mean difference, 0.06 kPa; standard deviation [SD], 0.81; range, −1.36 to 4.30). The Mann–Whitney–Wilcoxon test showed no significant differences between pre- and post-Gd-EOB-DTPA hepatic stiffness values ($p = 0.49$).

The classification of patients according to their mean stiffness values into different fibrosis stages led to the following results for pre-Gd-EOB-DTPA measurements: 15 patients were classified as stage F0 (normal hepatic tissue); seven as stage F1; 13, stage F2; seven, stage F3; and five, stage F4. Regarding the post-Gd-EOB-DTPA data, 12 patients were classified as stage F0; 11, stage F1; 12, stage F2; seven, stage F3; and five, stage F4. The resulting contingency table is presented as Table 3. The overall agreement was 87.23%; Cohen’s kappa was 0.84. The Pearson chi-squared test was highly significant ($p < 0.001$) and the two-way intraclass correlation coefficient was 0.96 (95% confidence interval, 93.7–98), indicating excellent agreement. Overall, the obtained

![Stiffness pre/post-Gd-EOB-DTPA](image-url)
fibrosis stage deviated between pre- and post-Gd-EOB-DTPA measurements in only six patients. The individual mean stiffness values for these patients are listed in Table 4. In all cases, the mean stiffness value was near the range limit of the respective fibrosis stage, and the mean difference between pre- and post-stiffness values was $-0.16$ kPa (range: $-0.44$ – $0.29$).

Typical exemplary stiffness maps are shown in Figs. 4 and 5 together with corresponding magnitude and wave images.

Discussion

Hepatic MRI with Gd-EOB-DTPA administration is a standard imaging procedure for the assessment of various hepatic conditions [16]. The additional benefits of hepatic MRE attracts increasing interest, and several centres have already included MRE into the routine hepatic MRI protocol to evaluate diffuse liver disease and characterise focal lesions [17].

Our results indicate a high, significant correlation between pre- and post-Gd-EOB-DTPA stiffness values (Pearson correlation coefficient of $r = 0.95$; $p < 0.001$), with no significant differences between the two values ($p = 0.49$). Furthermore, no systematic effect was observed for the difference between pre- and post-stiffness measurements (mean difference, 0.06 kPa; SD, 0.81) using the Bland–Altman plot.

In our study, the classification of patients into fibrosis stages indicated an excellent agreement between pre- and post-MRE measurements. Only six of the 47 patients displayed a different assignment on comparing the pre- and post-Gd-EOB-DTPA stiffness measurements. In these cases, the values were very close to the defined cut-off level between two stages, with a maximum absolute difference of stiffness values of only 0.44 kPa. A possible reason for these overall small differences could be slightly different slice locations of the transverse sections through the liver after repositioning the patient for the second examination. In this context a possible influence due to a slightly different driver position could also be discussed [18].

To the best of our knowledge, this is the first study to evaluate the effect of liver-specific contrast medium administration on hepatic MRE stiffness measurements performed before and after (40–50 min) the administration in the DHBP. By this time, Gd-EOB-DTPA has entirely been taken up by the hepatocytes, increasing the T1 relaxation and raising the normal liver signal intensity, which may theoretically influence the stiffness measurements [19]. Halinan et al reported that intravenous gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA) has no significant influence on liver stiffness measurements using hepatic MRE and does not significantly affect the diagnostic performance of hepatic MRE for fibrosis detection [20]. As opposed to our study, the authors did not use a liver-specific contrast medium and performed hepatic MRE measurements before and 5 min after intravenous...
contrast medium injection. Motosugi et al hypothesised that the phase shift of the contrast medium does not affect the stiffness measurements obtained using hepatic MRE [21] and demonstrated the lack of influence of Gd-EOB-DTPA on hepatic MRE stiffness measurements in their study. However, their post-contrast medium measurements were performed 20 min after Gd-EOB-DTPA administration, with the patient remaining on the scanning table between the two hepatic MRE acquisitions.

Fig. 4 Example of hepatic MRE with stiffness measurements performed before (e) and after (f) Gd-EOB-DTPA administration together with the respective magnitude (a, b) and wave (c, d) images. The resulting mean hepatic stiffness value for (e) was 4.98 kPa and (f) was 4.83 kPa, both indicating fibrosis grade F3. The dotted line represents the measured area of the liver parenchyma within the 95% confidence map.

### Table 4

| Patient (no.) | Fibrosis stage pre-Gd-EOB-DTPA | Fibrosis stage post-Gd-EOB-DTPA | Mean stiffness pre-Gd-EOB-DTPA | Mean stiffness post-Gd-EOB-DTPA | Stiffness difference |
|---------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|---------------------|
| 1             | 2                             | 1                             | 3.025                         | 2.861                         | 0.164               |
| 2             | 1                             | 2                             | 2.703                         | 3.099                         | −0.396              |
| 3             | 0                             | 1                             | 2.441                         | 2.884                         | −0.443              |
| 4             | 2                             | 1                             | 3.249                         | 2.957                         | 0.292               |
| 5             | 0                             | 1                             | 2.265                         | 2.616                         | −0.351              |
| 6             | 0                             | 1                             | 2.318                         | 2.529                         | −0.210              |

Owing to its structure, Gd-EOB-DTPA is rapidly absorbed at a high dose by hepatocytes, leading to better visualisation of normal hepatic tissue through parenchymal enhancement [22]. Some studies have indicated that without reaching statistical significance, Gd-EOB-DTPA can influence DWI and T2-weighted images by causing higher magnetic susceptibility and T2 shortening [23, 24]. In general, the DHBP with Gd-EOB-DTPA is acquired about 20 min after contrast administration, because at this time normal hepatocytes reach...
maximum signal intensity [25]. However, the time of contrast uptake may differ between individuals because the hepatic elimination pathway is related to hepatocyte function [26]. Studies indicate that enhancement of liver parenchyma is best at 20 min after administration of Gd-EOB-DTPA followed by a signal intensity plateau for at least 2 h [27, 28]. It is known that the Gd-EOB-DTPA transport correlates with liver function and therefore the peak of Gd-EOB-DTPA accumulation in a damaged liver is delayed [29]. Thus, in compromised liver parenchyma (e.g. fibrotic or cirrhotic) the hepatobiliary phase may be delayed due to the reduced liver function [6, 30, 31]. For this reason, at our centre, whenever liver MRI is performed on patients with clinical suspicion of impaired liver function, a second imaging session with new patient positioning in the scanner is performed 40–50 min after the first examination. The idea behind the present study was to assess if MRE could be performed during this second session. In this case the initial session could be kept relatively short and the MRE driver would not have to be applied during this session, possibly leading to easier breathing and breath-holding for patients. This is relevant to well-known problems of arterial phase imaging with Gd-EOB-DTPA, which has been recently associated with acute transient dyspnoea [32, 33]. The hepatic protocol is an exhausting examination for patients, especially when their general condition is restricted. Therefore, the MRI examination should be performed as pleasantly as possible, with the best possible image quality.

For MRE, motion encoding gradients are used, leading to prolonged echo times and consequently to decreased image quality in case of T2 or T2* reduction, as for example is the case for iron overload [34]. Therefore, especially when based on GRE sequences, increased iron levels are often a limiting factor for MRE [35]. As contrast agents lead to a T2 and T2* reduction, these effects might likewise be a limiting factor for MRE quality. However, in contrast to iron, for Gd-EOB-DTPA the corresponding T1 effect dominates, because T1 and T2 relaxivities are of approximately the same magnitude [36]. Therefore, for our MRE sequence, the T1 effect of the contrast agent compensates any signal decrease due to the simultaneous T2 and T2* shortening, and the image quality
with and without contrast agent is comparable or even tends to be superior after contrast administration. In our patient cohort only one patient showed slight iron overload and no notable decrease in image quality could be found. Our objective was to evaluate liver stiffness values before and after contrast administration so that even if iron was present, its effect remained the same in both sessions. When dealing with patients suffering from iron overload, spin echo-based echo planar imaging, fast spin echo methods or T1-based tagged MRI are more reliable methods than GRE sequences as used in our study [37, 38].

Our study has some limitations that must be addressed. First, our study population was rather small compared with those of other studies. Furthermore, some conditions, e.g. inflammation, congestion, portal hypertension and cholestasis, can also cause increased liver stiffness [39]. Kim et al [40] illustrated in their recent paper that liver stiffness measured by MRE increases as cholestasis increases. This effect was not ruled out in our study, so it might be possible that in patients with modest biliary obstruction administration of Gd-EOB-DTPA might cause a transient rise in liver stiffness. Another drawback is that no histological correlation was available; however, the purpose of our study was not to evaluate whether hepatic MRE findings correlated with clinical or histological findings (which have been assessed in several other studies [41, 42]), but to compare the results within individuals’ data. Furthermore, it was not possible to prove that MRI without passive driver administration really improves the quality of the examination because our study did not include MRI examinations without a passive driver. Hence, this statement remains a hypothesis that needs to be tested in another study. We used a two-dimensional phase-contrast GRE sequence to gather three transverse slices through the liver parenchyma and manually positioned an as large as possible polygonal ROI within the 95% confidence region of the acquired stiffness maps. This generally accepted method [43] allows the evaluation of a large portion, but not of the entire organ, because usually the 95% confidence region with reliable stiffness values is smaller than the entire liver [8]. The use of true three-dimensional imaging could be alternatively discussed, even though longer acquisition times might be problematic for breath-holding [18], and these methods are not yet commercially available. Technical details to improve image quality need to be evaluated in future studies. Finally, inter- and intra-observer variability was not evaluated in our study; however, reproducibility and repeatability of MRE measurements for staging of liver fibrosis were already studied in detail by Lee et al [44].

In conclusion, Gd-EOB-DTPA administration does not significantly influence hepatic MRE stiffness measurements in the DHBP. 40–50 min after contrast medium administration. Therefore, for daily clinical routine, hepatic MRE measurements can reliably be performed at any time in the DHBP.

Acknowledgements Open access funding provided by University of Innsbruck and Medical University of Innsbruck.

Funding The authors state that this work has not received any funding.

Compliance with ethical standards

Guarantor The scientific guarantor of this publication is PD Dr. Benjamin Henninger.

Conflict of interest The authors of this paper declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Statistics and biometry One of the authors has significant statistical expertise.

Informed consent Written informed consent was not required for this study because of its retrospective nature; it was waived by the Institutional Review Board.

Ethical approval Institutional Review Board approval was not required because of the retrospective nature of this study. It was granted by means of a general waiver.

Methodology

- retrospective
- diagnostic prognostic study
- study performed at one institution

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Low G, Kruse SA, Lomas DJ (2016) General review of magnetic resonance elastography. World J Radiol 8:59–72
2. Venkatesh SK, Yin M, Ehman RL (2013) Magnetic resonance elastography of liver: clinical applications. J Comput Assist Tomogr 37:887–896
3. Godfrey EM, Mannelli L, Griffin N, Lomas DJ (2013) Magnetic resonance elastography in the diagnosis of hepatic fibrosis. Semin Ultrasound CT MR 34:81–88
4. Haimerl M, Wachtler M, Zeman F et al (2014) Quantitative evaluation of enhancement patterns in focal solid liver lesions with Gd-EOB-DTPA-enhanced MRI. PLoS One 9:e100315
5. Van Beers BE, Pastor CM, Hassain HK (2012) Primovist, Eovist: what to expect? J Hepatol 57:421–429
6. Neri E, Bali MA, Ba-Ssalamah A et al (2016) ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 26:921–931
7. Goodwin MD, Dobson JE, Sirlin CB, Lim BG, Stella DL (2011) Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics 31:1547–1568
8. Venkatesh SK, Ehman RL (2015) Magnetic resonance elastography of abdomen. Abdom Imaging 40:745–759
9. Zhong X, Nickel MD, Kannengiesser SA, Dale BM, Kiefer B, Bashir MR (2014) Liver fat quantification using a multi-step adaptive fitting approach with multi-echo GRE imaging. Magn Reson Med 72:1353–1365

10. Imaizumi K, Kessoku T, Honda Y et al (2016) Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology 150(626-637):e627

11. Mariappan YK, Glaser KJ, Ehman RL (2010) Magnetic resonance elastography: a review. Clin Anat 23:497–511

12. Henninger B, Zoller H, Kannengiesser S, Zhong X, Jaschke W, Kremsner C (2017) 3D Multi Echo Dixon for the evaluation of hepatic iron and fat in a clinical setting. J Magn Reson Imaging 46:793–800

13. Adams P, Brissot P, Powell LW (2000) EASL International Consensus Conference on Haemochromatosis. J Hepatol 33:485–504

14. R Development Core Team 2006 (2017) The R Project for Statistical Computing Version 3.4.0. Available via http://www.R-project.org

15. Matthias Gamer JL, Ian Fellows Puspender Singh (2012) Various Coefficients of Interrater Reliability and Agreement. R package version 0.84. Available via https://CRAN.R-project.org/package=irr

16. Golferri R, Garzillo G, Asciano S, Renzulli M (2014) Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines. Dig Dis 32:696–704

17. Venkatesh SK, Ehman RL (2014) Magnetic resonance elastography of liver. Magn Reson Imaging Clin N Am 22:433–446

18. Mannelli L, Godfrey E, Joubert I et al (2010) MR elastography: Spleen stiffness measurements in healthy volunteers—preliminary experience. AJR Am J Roentgenol 195:387–392

19. Ringe KI, Husarik DB, Sirlin CB, Merkle EM (2010) Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 195:23–28

20. Hallinan JT, Alsaih WS, Wee A, Venkatesh SK (2015) Magnetic resonance elastography of liver: influence of intravenous gadolinium administration on measured liver stiffness. Abdom Imaging 40:783–788

21. Motosugi U, Ichikawa T, Sou H et al (2012) Effects of gadoxetic acid on liver elasticity measurement by using magnetic resonance elastography. Magn Reson Imaging 30:128–132

22. Giovanetti A, Paci E (1996) Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA-Dimeg). Magn Reson Imaging Clin N Am 4:61–72

23. Chiu FY, Jao JC, Chen CY et al (2005) Effect of intravenous gadolinium-DTPA on diffusion-weighted magnetic resonance images for evaluation of focal hepatic lesions. J Comput Assist Tomogr 29:176–180

24. Choi JS, Kim MJ, Choi JY, Park MS, Lim JS, Kim KW (2010) Diffusion-weighted MR imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium. Eur Radiol 20:1052–1060

25. Palmucci S (2014) Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI. World J Hepatol 6:477–485

26. Verloh N, Haimerl M, Rennert J et al (2013) Impact of liver cirrhosis on liver enhancement at Gd-EOB-DTPA enhanced MRI at 3 Tesla. Eur J Radiol 82:1710–1715

27. Hamm B, Staks T, Mühler A et al (1995) Phase I clinical evaluation of Gad-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792

28. Reimer P, Rummery EJ, Shamsi K et al (1996) Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 199:177–183

29. Tsuda N, Okada M, Murakami T (2007) Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 42:242–247

30. Phongkitkarun S, Limsamutpetch K, Tanaphai P, Jatchavala J (2013) Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients. World J Gastroenterol 19:8357–8365

31. Chemyak V, Kim J, Rozinbalt AM, Mazzoroli F, Ricci Z (2011) Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: the role of laboratory factors. J Magn Reson Imaging 34:301–309

32. Davenport MS, Viglianti BL, Al-Hawary MM et al (2013) Comparison of acute transient dyspea after intravenous administration of gadobenate dimeglumine: effect on arterial phase image quality. Radiology 266:452–461

33. Fujiinaga Y, Kitou Y, Ohya A et al (2016) Advantages of radial volumetric breath-hold examination (VIBE) with k-space weighted image contrast reconstruction (KWIC) over Cartesian VIBE in liver imaging of volunteers simulating inadequate or no breath-holding ability. Eur Radiol 26:2790–2797

34. Mannelli L, Godfrey E, Graves MJ et al (2012) Magnetic resonance elastography: feasibility of liver stiffness measurements in healthy volunteers at 3T. Clin Radiol 67:258–262

35. Singh S, Venkatesh SK, Wang Z et al (2015) Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 13(440-451):e446

36. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weimann HJ (2005) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 40:715–724

37. Venkatesh SK, Yin M, Ehman RL (2013) Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging 37:544–555

38. Mannelli L, Wilson GJ, Dubinsky TJ et al (2012) Assessment of the liver strain among cirrhotic and normal livers using tagged MRI. J Magn Reson Imaging 36:1490–1495

39. Garteser P, Doblas S, Van Beers BE (2018) Magnetic resonance elastography of liver and spleen: Methods and applications. NMR Biomed. https://doi.org/10.1002/nbm.3891

40. Kim DK, Choi JY, Park MS, Kim MJ, Chung YE (2018) Clinical Feasibility of MR Elastography in Patients With Biliary Obstruction. AJR Am J Roentgenol. https://doi.org/10.2214/AJR.17.19085:1-6

41. Wang Y, Ganger DR, Levitsky J et al (2011) Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol 196:553–561

42. Toguchi M, Tsunusaki M, Yada N et al (2017) Magnetic resonance elastography in the assessment of hepatic fibrosis: a study comparing transient elastography and histological data in the same patients. Abdom Radiol (NY) 42:1659–1666

43. Serai SD, Obuchowski NA, Venkatesh SK et al (2017) Repeatability of MR Elastography of Liver: A Meta-Analysis. Radiology 285:92–100

44. Lee Y, Lee JM, Lee JE et al (2014) MR elastography for noninvasive assessment of hepatic fibrosis: reproducibility of the examination and reproducibility and repeatability of the liver stiffness value measurement. J Magn Reson Imaging 39:326–331